-
1
-
-
80054914456
-
Breast and cervical cancer in 187 countries between 1980 and 2010: A systematic analysis
-
Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: A systematic analysis. Lancet 2011;378:1461-84.
-
(2011)
Lancet
, vol.378
, pp. 1461-1484
-
-
Forouzanfar, M.H.1
Foreman, K.J.2
Delossantos, A.M.3
Lozano, R.4
Lopez, A.D.5
Murray, C.J.6
-
2
-
-
0032189117
-
Treatment of breast cancer
-
Hortobagyi GN. Treatment of breast cancer. N Engl J Med 1998;339:974-84.
-
(1998)
N Engl J Med
, vol.339
, pp. 974-984
-
-
Hortobagyi, G.N.1
-
3
-
-
37049183697
-
Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
-
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
-
(1987)
Science
, vol.235
, pp. 177-182
-
-
Slamon, D.J.1
Clark, G.M.2
Wong, S.G.3
Levin, W.J.4
Ullrich, A.5
McGuire, W.L.6
-
4
-
-
77955003205
-
Confirmation of a low HER2 positivity rate of breast carcinomas-limitations of immunohistochemistry and in situ hybridization
-
Vogel UF. Confirmation of a low HER2 positivity rate of breast carcinomas-limitations of immunohistochemistry and in situ hybridization. Diagn Pathol 2010;5:50.
-
(2010)
Diagn Pathol
, vol.5
, pp. 50
-
-
Vogel, U.F.1
-
5
-
-
18244422222
-
HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas
-
Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997;15:2894-904.
-
(1997)
J Clin Oncol
, vol.15
, pp. 2894-2904
-
-
Press, M.F.1
Bernstein, L.2
Thomas, P.A.3
Meisner, L.F.4
Zhou, J.Y.5
Ma, Y.6
-
6
-
-
0032078876
-
ERBB2 oncogene in human breast cancer and its clinical significance
-
Révillion F, Bonneterre J, Peyrat JP. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 1998;34:791-808.
-
(1998)
Eur J Cancer
, vol.34
, pp. 791-808
-
-
Révillion, F.1
Bonneterre, J.2
Peyrat, J.P.3
-
7
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
-
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
-
(2001)
N Engl J Med
, vol.344
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
Fuchs, H.4
Paton, V.5
Bajamonde, A.6
-
8
-
-
26844503270
-
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
-
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
-
(2005)
N Engl J Med
, vol.353
, pp. 1659-1672
-
-
Piccart-Gebhart, M.J.1
Procter, M.2
Leyland-Jones, B.3
Goldhirsch, A.4
Untch, M.5
Smith, I.6
-
9
-
-
26844536978
-
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
-
Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
-
(2005)
N Engl J Med
, vol.353
, pp. 1673-1684
-
-
Romond, E.H.1
Perez, E.A.2
Bryant, J.3
Suman, V.J.4
Geyer, C.E.5
Davidson, N.E.6
-
10
-
-
80053539103
-
Adjuvant trastuzumab in HER2-positive breast cancer
-
Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365:1273-83.
-
(2011)
N Engl J Med
, vol.365
, pp. 1273-1283
-
-
Slamon, D.1
Eiermann, W.2
Robert, N.3
Pienkowski, T.4
Martin, M.5
Press, M.6
-
11
-
-
33751344602
-
HER2 therapy: Molecular mechanisms of trastuzumab resistance
-
Nahta R, Esteva FJ. HER2 therapy: Molecular mechanisms of trastuzumab resistance. Breast Cancer Res 2006;8:215.
-
(2006)
Breast Cancer Res
, vol.8
, pp. 215
-
-
Nahta, R.1
Esteva, F.J.2
-
12
-
-
79952162826
-
HER2-amplified breast cancer: Mechanisms of trastuzumab resistance and novel targeted therapies
-
Gajria D, Chandarlapaty S. HER2-amplified breast cancer: Mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther 2011;11:263-75.
-
(2011)
Expert Rev Anticancer Ther
, vol.11
, pp. 263-275
-
-
Gajria, D.1
Chandarlapaty, S.2
-
13
-
-
84869781977
-
Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer
-
Mohd Sharial MS, Crown J, Hennessy BT. Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer. Ann Oncol 2012;23:3007-16.
-
(2012)
Ann Oncol
, vol.23
, pp. 3007-3016
-
-
Mohd Sharial, M.S.1
Crown, J.2
Hennessy, B.T.3
-
14
-
-
20244388653
-
Study of the biologic effects of lapatinib a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases on tumor growth and survival pathways in patients with advanced malignancies
-
Spector NL, Xia W, Burris H 3 rd, Hurwitz H, Dees EC, Dowlati A, et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005;23:2502-12.
-
(2005)
J Clin Oncol
, vol.23
, pp. 2502-2512
-
-
Spector, N.L.1
Xia, W.2
Burris, H.3
Hurwitz, H.4
Dees, E.C.5
Dowlati, A.6
-
15
-
-
33845886440
-
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
-
Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43.
-
(2006)
N Engl J Med
, vol.355
, pp. 2733-2743
-
-
Geyer, C.E.1
Forster, J.2
Lindquist, D.3
Chan, S.4
Romieu, C.G.5
Pienkowski, T.6
-
16
-
-
30544450275
-
Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells
-
Xia W, Gerard CM, Liu L, Baudson NM, Ory TL, Spector NL. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene 2005;24:6213-21.
-
(2005)
Oncogene
, vol.24
, pp. 6213-6221
-
-
Xia, W.1
Gerard, C.M.2
Liu, L.3
Baudson, N.M.4
Ory, T.L.5
Spector, N.L.6
-
17
-
-
32944461545
-
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells
-
Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006;66:1630-9.
-
(2006)
Cancer Res
, vol.66
, pp. 1630-1639
-
-
Konecny, G.E.1
Pegram, M.D.2
Venkatesan, N.3
Finn, R.4
Yang, G.5
Rahmeh, M.6
-
18
-
-
60149109196
-
Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity
-
Scaltriti M, Verma C, Guzman M, Jimenez J, Parra JL, Pedersen K, et al. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 2009;28:803-14.
-
(2009)
Oncogene
, vol.28
, pp. 803-814
-
-
Scaltriti, M.1
Verma, C.2
Guzman, M.3
Jimenez, J.4
Parra, J.L.5
Pedersen, K.6
-
19
-
-
77949884661
-
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer
-
Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010;28:1124-30.
-
(2010)
J Clin Oncol
, vol.28
, pp. 1124-1130
-
-
Blackwell, K.L.1
Burstein, H.J.2
Storniolo, A.M.3
Rugo, H.4
Sledge, G.5
Koehler, M.6
-
20
-
-
84864066561
-
Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: Final results from the EGF104900 Study
-
Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: Final results from the EGF104900 Study. J Clin Oncol 2012;30:2585-92.
-
(2012)
J Clin Oncol
, vol.30
, pp. 2585-2592
-
-
Blackwell, K.L.1
Burstein, H.J.2
Storniolo, A.M.3
Rugo, H.S.4
Sledge, G.5
Aktan, G.6
-
21
-
-
84857236823
-
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, open-label, multicentre, phase 3 trial
-
Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, open-label, multicentre, phase 3 trial. Lancet 2012;379:633-40.
-
(2012)
Lancet
, vol.379
, pp. 633-640
-
-
Baselga, J.1
Bradbury, I.2
Eidtmann, H.3
Di Cosimo, S.4
De Azambuja, E.5
Aura, C.6
-
22
-
-
84864018421
-
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: Results of the randomized phase II CHER-LOB study
-
Guarneri V, Frassoldati A, Bottini A, Cagossi K, Bisagni G, Sarti S, et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: Results of the randomized phase II CHER-LOB study. J Clin Oncol 2012;30:1989-95.
-
(2012)
J Clin Oncol
, vol.30
, pp. 1989-1995
-
-
Guarneri, V.1
Frassoldati, A.2
Bottini, A.3
Cagossi, K.4
Bisagni, G.5
Sarti, S.6
-
23
-
-
84885416696
-
Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer
-
abstract 500
-
Carey LA, Berry DA, Ollila D, Harris L, Krop IE, Weckstein D, et al. Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer. J Clin Oncol 2013;31 Suppl 15:abstract 500.
-
(2013)
J Clin Oncol
, vol.31
-
-
Carey, L.A.1
Berry, D.A.2
Ollila, D.3
Harris, L.4
Krop, I.E.5
Weckstein, D.6
-
24
-
-
84879473563
-
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006
-
Rimawi MF, Mayer IA, Forero A, Nanda R, Goetz MP, Rodriguez AA, et al. Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol 2013;31:1726-31.
-
(2013)
J Clin Oncol
, vol.31
, pp. 1726-1731
-
-
Rimawi, M.F.1
Mayer, I.A.2
Forero, A.3
Nanda, R.4
Goetz, M.P.5
Rodriguez, A.A.6
-
25
-
-
84868205001
-
Dual human epidermal growth factor receptor 2 blockade: Another step forward in treating patients with human epidermal growth factor receptor 2-positive breast cancer
-
Zardavas D, Bozovic-Spasojevic I, de Azambuja E. Dual human epidermal growth factor receptor 2 blockade: Another step forward in treating patients with human epidermal growth factor receptor 2-positive breast cancer. Curr Opin Oncol 2012;24:612-22.
-
(2012)
Curr Opin Oncol
, vol.24
, pp. 612-622
-
-
Zardavas, D.1
Bozovic-Spasojevic, I.2
De, A.E.3
-
26
-
-
65349110371
-
Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A German breast group 26/breast international group 03-05 study
-
von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A German breast group 26/breast international group 03-05 study. J Clin Oncol 2009;27:1999-2006.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1999-2006
-
-
Von G, M.1
Bois Du, A.2
Schmidt, M.3
Maass, N.4
Cufer, T.5
De Fe, J.6
-
27
-
-
73149115341
-
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer
-
Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009;27:5538-46.
-
(2009)
J Clin Oncol
, vol.27
, pp. 5538-5546
-
-
Johnston, S.1
Pippen, J.2
Pivot, X.3
Lichinitser, M.4
Sadeghi, S.5
Dieras, V.6
-
28
-
-
84871722407
-
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): A single-group phase 2 study
-
Bachelot T, Romieu G, Campone M, Diéras V, Cropet C, Dalenc F, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): A single-group phase 2 study. Lancet Oncol 2013;14:64-71.
-
(2013)
Lancet Oncol
, vol.14
, pp. 64-71
-
-
Bachelot, T.1
Romieu, G.2
Campone, M.3
Diéras, V.4
Cropet, C.5
Dalenc, F.6
-
29
-
-
44949253343
-
Cardiac safety of lapatinib: Pooled analysis of 3689 patients enrolled in clinical trials
-
Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS. Cardiac safety of lapatinib: Pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 2008;83:679-86.
-
(2008)
Mayo Clin Proc
, vol.83
, pp. 679-686
-
-
Perez, E.A.1
Koehler, M.2
Byrne, J.3
Preston, A.J.4
Rappold, E.5
Ewer, M.S.6
-
31
-
-
84882674891
-
Cardiac toxicity in breast cancer patients treated with dual HER2 blockade
-
Valachis A, Nearchou A, Polyzos NP, Lind P. Cardiac toxicity in breast cancer patients treated with dual HER2 blockade. Int J Cancer 2013;133:2245-52.
-
(2013)
Int J Cancer
, vol.133
, pp. 2245-2252
-
-
Valachis, A.1
Nearchou, A.2
Polyzos, N.P.3
Lind, P.4
|